The company was founded in 1998 and develops innovative, minimally invasive technologies that provide benefits for both patients and healthcare systems. Our group consists of professional staff, with leaders in the fields of physics and engineering, as well as clinical experts.
The lead product, Synergo® RITE (Radiofrequency-Induced Thermo Chemotherapeutic Effect), offers a clinically effective, safe, and easy way to deliver a tri-modality local treatment combining non-ionizing radiofrequency radiation, chemotherapy, and deep tissue hyperthermia, targeted directly at the tissue by the RF. Synergo® treatment has become a common practice in leading centers in Israel, Europe, and the UK.
The treatment is given both as a prophylactic treatment (after TUR) and as an ablative treatment (for tumor eradication). The prophylactic induction phase includes 6 weekly sessions, followed by 6 in a “maintenance” phase, once every 6 weeks.
For clinical trials and results, please visit the company's website.
Potential Business Partners: Distributors of medical equipment active in urology departments, employing technicians and product specialists, who evaluate the country’s reimbursement system (including insurers and treatment codes).
Target Countries: Worldwide, focusing on the UK, Germany, and Singapore.
